Panitumumab and Irinotecan for Malignant Gliomas
This study has been terminated.
(study did not reach benchmark efficacy rule at 16 subjects)
Sponsor:
Annick Desjardins
Collaborator:
Amgen
Information provided by (Responsible Party):
Annick Desjardins, Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT01017653
First received: November 19, 2009
Last updated: February 13, 2013
Last verified: February 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | October 2011 |
| Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |